Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Citizens Business Bank

Citizens Business Bank trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,647 shares of the biopharmaceutical company’s stock after selling 206 shares during the period. Citizens Business Bank’s holdings in Gilead Sciences were worth $557,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Rehmann Capital Advisory Group raised its holdings in Gilead Sciences by 3.6% in the 3rd quarter. Rehmann Capital Advisory Group now owns 9,626 shares of the biopharmaceutical company’s stock valued at $807,000 after acquiring an additional 333 shares during the last quarter. TD Private Client Wealth LLC raised its position in Gilead Sciences by 10.6% in the third quarter. TD Private Client Wealth LLC now owns 57,509 shares of the biopharmaceutical company’s stock valued at $4,822,000 after purchasing an additional 5,497 shares during the period. TT International Asset Management LTD acquired a new position in shares of Gilead Sciences in the third quarter worth $1,257,000. Coldstream Capital Management Inc. grew its stake in shares of Gilead Sciences by 9.8% in the third quarter. Coldstream Capital Management Inc. now owns 22,882 shares of the biopharmaceutical company’s stock worth $1,932,000 after acquiring an additional 2,043 shares in the last quarter. Finally, Gould Capital LLC grew its stake in shares of Gilead Sciences by 22.2% in the third quarter. Gould Capital LLC now owns 16,128 shares of the biopharmaceutical company’s stock worth $1,352,000 after acquiring an additional 2,927 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Up 1.9 %

Gilead Sciences stock opened at $92.34 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm has a 50-day moving average price of $89.33 and a two-hundred day moving average price of $78.89. The firm has a market capitalization of $115.08 billion, a price-to-earnings ratio of 1,026.00, a PEG ratio of 2.86 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the previous year, the firm earned $2.29 EPS. Gilead Sciences’s revenue was up 7.0% on a year-over-year basis. Sell-side analysts expect that Gilead Sciences, Inc. will post 4.37 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.34%. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. The trade was a 64.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. The trade was a 1.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 476,591 shares of company stock worth $43,747,615. 0.29% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Bank of America reaffirmed a “buy” rating and issued a $109.00 target price on shares of Gilead Sciences in a report on Tuesday. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target for the company. Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, Wells Fargo & Company increased their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Twelve research analysts have rated the stock with a hold rating, twelve have given a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $96.43.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.